The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials
Open accessAbstract
AIMS: The efficacy of durable polymer drug-eluting stents (DES) is delivered at the expense of delayed healing of the stented vessel. Biodegradable polymer DES aim to avoid this shortcoming and may potentially improve long-term clinical outcomes, with benefit expected to accrue over time. We sought to compare long-term outcomes in patients treated with biodegradable polymer DES vs. durable polymer sirolimus-eluting stents (SES). METHODS AND RESULTS: We pooled individual patient data from three large-scale multicentre randomized clinical trials (ISAR-TEST 3, ISAR-TEST 4, and LEADERS) comparing biodegradable polymer DES with durable polymer SES and assessed clinical outcomes during follow-up through 4 years. The efficacy endpoint of interest was target lesion revascularization and the safety endpoint of interest was definite stent thrombosis. Out of 4062 patients included in the present analysis, 2358 were randomly assigned to treatment with biodegradable polymer DES (sirolimus-eluting, n= 1501; biolimus-eluting, n= 857) and 1704 patients to durable polymer SES. No heterogeneity across the trials was observed in analyses of the primary and secondary endpoints. At 4 years, the risk of target lesion revascularization was significantly lower among patients treated with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.82, 95% CI 0.68-0.98, P= 0.029). In addition, the risk of stent thrombosis was significantly reduced with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.56, 95% CI 0.35-0.90, P= 0.015), driven by a lower risk of very late stent thrombosis (hazard ratio 0.22, 95% CI 0.08-0.61, P= 0.004). In keeping with this, in landmark analysis between 1 and 4 years, the incidence of myocardial infarction was lower for patients treated with biodegradable polymer DES vs. durable polymer SES (hazard ratio 0.59, 95% CI 0.73-0.95, P= 0.031). CONCLUSION: Biodegradable polymer DES improve safety and efficacy compared with durable polymer SES during long-term follow-up to 4 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationPathology of Drug-Eluting Stents in Humans
Joner, M., Finn, A. V., Farb, A., Mont, E. K., Kolodgie, F. D., Ladich, E., Kutys, R., Skorija, K., Gold, H. K., & Virmani, R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.042 · Cited by 2,744
Systematic Reviews in Health Care : Meta-Analysis in Context
Egger, M., Smith, G. D., & Altman, D. G. (2000) · Cited by 2,401
Systematic Reviews in Health Care: Meta‐Analysis in Context
(2001) · doi:10.1002/9780470693926 · Cited by 1,693
Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents
Stone, G. W., Moses, J. W., Ellis, S. G., Schofer, J., Dawkins, K. D., Morice, M.-C., Colombo, A., Schampaert, E., Grube, E., Kirtane, A. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067193 · Cited by 1,631
Virmani, R., Guagliumi, G., Farb, A., Musumeci, G., Grieco, N., Motta, T., Mihalcsik, L., Tespili, M., Valsecchi, O., & Kolodgie, F. D. (2004) · Circulation · doi:10.1161/01.cir.0000116202.41966.d4 · Cited by 1,469
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
Stettler, C., Wandel, S., Allemann, S., Kastrati, A., Morice, M. C., Schömig, A., Pfisterer, M. E., Stone, G. W., Leon, M. B., de Lezo, J. S., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61444-5 · Cited by 1,428
Self-citationAnalysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Kastrati, A., Mehilli, J., Pache, J., Kaiser, C., Valgimigli, M., Kelbæk, H., Menichelli, M., Sabaté, M., Suttorp, M. J., Baumgart, D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067484 · Cited by 1,006
Self-citationVascular Responses to Drug Eluting Stents: Importance of Delayed Healing
Finn, A. V., Nakazawa, G., Joner, M., Kolodgie, F. D., Mont, E. K., Gold, H. K., & Virmani, R. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.144220 · Cited by 900
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents
Spaulding, C., Daemen, J., Boersma, E., Cutlip, D. E., & Serruys, P. W. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066633 · Cited by 704
Self-citationWindecker, S., Serruys, P. W., Wandel, S., Buszman, P., Trznadel, S., Linke, A., Lenk, K., Ischinger, T., Klauss, V., Eberli, F., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61244-1 · Cited by 653
Self-citationNakazawa, G., Finn, A. V., Joner, M., Ladich, E., Kutys, R., Mont, E. K., Gold, H. K., Burke, A. P., Kolodgie, F. D., & Virmani, R. (2008) · Circulation · doi:10.1161/circulationaha.107.762047 · Cited by 611
Incidence and Correlates of Drug-Eluting Stent Thrombosis in Routine Clinical Practice
Wenaweser, P., Daemen, J., Zwahlen, M., van Domburg, R., Jüni, P., Vaina, S., Hellige, G., Tsuchida, K., Morger, C., Boersma, E., et al. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.006 · Cited by 481
Self-citationCook, S., Ladich, E., Nakazawa, G., Eshtehardi, P., Neidhart, M., Vogel, R., Togni, M., Wenaweser, P., Billinger, M., Seiler, C., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.854398 · Cited by 480
Self-citationStefanini, G. G., Kalesan, B., Serruys, P. W., Heg, D., Buszman, P., Linke, A., Ischinger, T., Klauss, V., Eberli, F., Wijns, W., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61672-3 · Cited by 354
Self-citationClinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents
Win, H. K., Caldera, A. E., Maresh, K., Lopez, J., Rihal, C. S., Parikh, M. A., Granada, J. F., Marulkar, S., Nassif, D., Cohen, D. J., et al. (2007) · JAMA · doi:10.1001/jama.297.18.2001 · Cited by 343
Sterne, J. A. C., Bradburn, M. J., & Egger, M. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch18 · Cited by 297
Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting Stents
Beohar, N., Davidson, C. J., Kip, K. E., Goodreau, L., Vlachos, H. A., Meyers, S. N., Benzuly, K. H., Flaherty, J. D., Ricciardi, M. J., Bennett, C. L., et al. (2007) · JAMA · doi:10.1001/jama.297.18.1992 · Cited by 270
A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications
Marroquin, O. C., Selzer, F., Mulukutla, S. R., Williams, D. O., Vlachos, H. A., Wilensky, R. L., Tanguay, J.-F., Holper, E. M., Abbott, J. D., Lee, J. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706258 · Cited by 270
Barlis, P., Regar, E., Serruys, P. W., Dimopoulos, K., van der Giessen, W. J., van Geuns, R.-J. M., Ferrante, G., Wandel, S., Windecker, S., van Es, G.-A., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp480 · Cited by 248
Self-citationByrne, R. A., Kastrati, A., Kufner, S., Massberg, S., Birkmeier, K. A., Laugwitz, K.-L., Schulz, S., Pache, J., Fusaro, M., Seyfarth, M., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp352 · Cited by 220
Self-citationMehilli, J., Byrne, R. A., Wieczorek, A., Iijima, R., Schulz, S., Bruskina, O., Pache, J., Wessely, R., Schomig, A., Kastrati, A., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn253 · Cited by 196
Self-citationRäber, L., Wohlwend, L., Wigger, M., Togni, M., Wandel, S., Wenaweser, P., Cook, S., Moschovitis, A., Vogel, R., Kalesan, B., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004762 · Cited by 186
Self-citationByrne, R. A., Kastrati, A., Maßberg, S., Wieczorek, A., Laugwitz, K., Hadamitzky, M., Schulz, S., Pache, J., Fusaro, M., Hausleiter, J., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.027 · Cited by 143
Self-citationDrug-Eluting Stents in Percutaneous Coronary Intervention
Byrne, R. A., Sarafoff, N., Kastrati, A., & Schömig, A. (2009) · Drug Safety · doi:10.2165/11316500-000000000-00000 · Cited by 68
Self-citationEverolimus-Eluting Versus Sirolimus-Eluting Stents
de Waha, A., Dibra, A., Byrne, R. A., Ndrepepa, G., Mehilli, J., Fusaro, M., Laugwitz, K., Maßberg, S., Schömig, A., & Kastrati, A. (2011) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.963256 · Cited by 61
Self-citation
Cited by
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
2014 ESC/EACTS Guidelines on myocardial revascularization
Kolh, P., Windecker, S., Alfonso, F., Collet, J.-P., Cremer, J., Falk, V., Filippatos, G., Hamm, C., Head, S. J., Jüni, P., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu366 · Cited by 4,199
Self-citationDrug-Eluting Coronary-Artery Stents
Stefanini, G. G., & Holmes, D. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1210816 · Cited by 728
Self-citationIbánez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2017.11.010 · Cited by 461
Self-citation
Metadata
- Authors
- Stefanini, G. G., Byrne, R. A., Serruys, P. W., de Waha, A., Meier, B., Massberg, S., Juni, P., Schomig, A., Windecker, S., & Kastrati, A.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-24
- Volume
- 33
- Issue
- 10
- Pages
- 1214-1222
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2118462279
- Cited by
- 384
- References
- 29
- FWCI
- 53.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.